Hypertension Prevalence Among Adults

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

Slideshow

From 2013-2016, about 46% of US adults had hypertension. Plus more highlights from the AHA's annual Heart Disease and Stroke Statistical Update.

The American Heart Association's annual report titled, "Heart Disease and Stroke Statistics: 2020 Update," provides the most up-to-date statistics related to heart disease, stroke, and cardiovascular (CV) risk factors, including health behaviors and health factors that contribute to CV health and CV-related morbidity and mortality.

The report is a critical resource for patients, physicians, and others seeking accurate data.

Scroll through our quick slideshow below for key points from the chapter on hypertension, focusing on prevalence among US adults.

Related Content

October 27th 2025

Weekly Dose Podcast: Arrhythmias as Early Risk Markers, Flu Vaccine Safety, Salt Substitute Use, Preconception CT Risks, and Global Diabetes Care Gaps

After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.

October 2nd 2025

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT scan risks, and global diabetes care gaps.

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.

September 24th 2025

Menopause Education Lags in Residency Training Across Primary Care Specialties

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease

Less than one-third of residents in IM, FM, and OB/GYN programs receive structured menopause training, leaving many unprepared for midlife women’s care.

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

A secondary analysis of the ELITE trial suggests that there may be a postmenopausal "critical window" during which use of MHT is optimal.

Related Content

October 27th 2025

Weekly Dose Podcast: Arrhythmias as Early Risk Markers, Flu Vaccine Safety, Salt Substitute Use, Preconception CT Risks, and Global Diabetes Care Gaps

After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.

October 2nd 2025

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT scan risks, and global diabetes care gaps.

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.

September 24th 2025

Menopause Education Lags in Residency Training Across Primary Care Specialties

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease

Less than one-third of residents in IM, FM, and OB/GYN programs receive structured menopause training, leaving many unprepared for midlife women’s care.